A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study

Table 2 Correlation between improvement in the DAS and each laboratory test before treatment

Laboratory test	TCZ group		TNF-i group
	R	p value	R	p value
Hemoglobin	0.56	0.003	−0.16	0.107
Platelet count	−0.42	0.023	0.19	0.063
Aspartate aminotransferase	0.46	0.014	0.21	0.053
Alanine aminotransferase	0.50	0.007	0.20	0.057
Lactate dehydrogenase	−0.11	0.324	0.22	0.185
Alkaline phosphatase	−0.25	0.154	−0.13	0.299
γ − Glutamiltranspeptidase	0.00	0.498	0.17	0.247
Blood urea nitrogen	0.19	0.189	−0.08	0.339
Creatinine	0.00	0.496	0.09	0.257
Total protein	−0.10	0.333	−0.28	0.078
Albumin	0.13	0.273	−0.29	0.011
Cholesterol	0.16	0.243	0.25	0.103
Low density lipoprotein	0.10	0.361	0.20	0.237
Iron	0.66	0.037	0.52	0.035
Ferritin	−0.31	0.152	0.41	0.063
Matrix metalloprotease 3	−0.13	0.283	0.16	0.151
Serum albumin A	−0.32	0.079	0.13	0.246
Rheumatoid factor	−0.06	0.403	0.18	0.310
Anticyclic citrullinated peptide antibody	0.04	0.444	0.80	0.101
Erythrocyte sedimentation rate	0.22	0.152	0.00	0.488
C reactive protein	−0.26	0.112	0.03	0.397

Correlation was tested between improvement in the DAS and each laboratory test before treatment in the tocilizumab (TCZ) group and the TNF inhibitor (TNF-i) group. There was significant correlation between the DAS ratio and hemoglobin, platelet count, aspartate aminotransferase, alanine aminotransferase, and iron in the TCZ group. The results were not similar in the TNF-i group, with the exception of correlation between the DAS ratio and iron

ISSN: 1478-6362